AIMS: Antiphosphatidylethanolamine antibodies (aPE) represent one type of antiphospholipid antibody (aPL) directed against the neutral phospholipids - phosphatidylethanolamines. The aim of this study was to evaluate levels and avidities of aPE in several groups of patients and compare them with conventional aPLs. METHODS: aPE were analysed in a cohort consisting of 68 hospitalized patients. The other cohort comprised 22 patients with immunologically-mediated diseases. The control group consisted of 20 healthy persons. ELISA methods were used for determination of aPL. Avidities of aPE were tested by modified ELISA with urea as a chaotropic agent. RESULTS: aPE IgG/IgM were significantly higher in the group of patients with venous thromboembolism than those with non-thrombotic internal disorders (P=0.02 for both Ig classes). aPE IgG/IgM elevated above cut-off values were found in 10.8% of patients with venous thromboembolism and as a single aPL in 6.5%. Levels of aPE IgG higher than our limit (>6 U/mL) were detected in 29% of patients with immunologically-mediated diseases with other positive aPL. Low-, intermediate- and high-avidity aPE IgG were found in patients of both cohorts. The avidities of aPE IgG differed from those of anticardiolipin antibodies IgG. Neither aPE IgG levels nor avidity dynamics significantly changed during follow-up. CONCLUSION: aPE may be related to venous thromboembolism and may be part of the repertoire of aPL in immunologically-mediated diseases. There are patients with thrombosis negative for conventional aPL but positive for aPE. aPE IgG may have different avidities.

Department of Health Care and Population Protection Faculty of Biomedical Engineering Czech Technical University Prague Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Thomayer University Hospital Czech Republic

See more in PubMed

Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498-509. DOI

Misasi R, Capozzi A, Longo A, Recalchi S, Lococo E, Alessandri C, Conti F, Valesini G, Sorice M. "New" antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome. J Immunol Res 2015;2015:858542. DOI

Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983;287:1088-9. PubMed DOI

Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, Salmon JE, Shoenfeld Y, Shovman O, Hunt BJ. Antiphospholipid syndrome. Nat Rev Dis Primers 2018;4:17103. PubMed DOI

Devreese KMJ, Ortel TL, Pengo V, de Laat B. Subcommittee on Lupus Anticoagulant/Antiphospholipid A. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018;16:809-13. DOI

Devreese KMJ. How to Interpret Antiphospholipid Laboratory Tests. Curr Rheumatol Rep 2020;22:38. PubMed DOI

Hughes GR, Khamashta MA. Seronegative antiphospholipid syndrome. Ann Rheum Dis 2003;62:1127. DOI

Bradacova P, Slavik L, Ulehlova J, Skoumalova A, Ullrychova J, Prochazkova J, Hlusi A, Manukyan G, Kriegova E. Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review. Biomedicines 2021;9:166. DOI

Zigon P, Podovsovnik A, Ambrozic A, Tomsic M, Hocevar A, Gaspersic N, Rotar Z, Praprotnik S, Semrl SS, Cucnik S. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements. Clin Rheumatol 2019;38:371-8. PubMed DOI

Tonello M, Mattia E, Favaro M, Del Ross T, Calligaro A, Salvan E, Hoxha A, Fedrigo M, Ruffatti A. IgG phosphatidylserine/prothrombin antibodies as a risk factor of thrombosis in antiphospholipid antibody carriers. Thromb Res 2019;177:157-60. DOI

Staub HL, Bertolaccini ML, Khamashta MA. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev 2012;12:230-4. PubMed DOI

Vance JE. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res 2008;49:1377-87. DOI

Zhixin L, Wells CW, North PE, Kumar S, Duris CB, McIntyre JA, Ming Z. Phosphatidylethanolamine at the luminal endothelial surface-implications for hemostasis and thrombotic autoimmunity. Clin Appl Thromb Hemost 2011;17:158-63. DOI

Butkiewicz F, Kaszuba M, Brzezinski M, Izbicki J, Kubis M, Lopinski H, Borowiak M, Szelepajlo M, Fischer K, Flicinski J. Associations between the incidence of antiphosphatidylserine and antiphosphatidylethanolamine antibodies and clinical manifestations of systemic lupus erythematosus. Pol Arch Med Wewn 2014;124:573-8. PubMed DOI

Dima A, Caraiola S, Jurcut C, Balanescu E, Balanescu P, Ramba D, Badea C, Pompilian V, Ionescu R, Baicus A, Baicus C, Dan GA. Extended Antiphospholipid Antibodies Screening in Systemic Lupus Erythematosus Patients. Rom J Intern Med 2015;53:321-8. DOI

Caraiola S, Jurcut C, Dima A, Baicus C, Baicus A. Antiphosphatidylethanolamine Antibodies and Deep Vein Thrombosis in Lupus Patients with Antiphospholipid Syndrome. Revista Romana De Medicina De Laborator 2018;26:243-50. DOI

Fialova L. Avidity of antiphospholipid antibodies - our current knowledge. Epidemiol Mikrobiol Imunol 2014;63:221-5.

Fialova L, Petrackova M, Kuchar O. Comparison of different enzyme-linked immunosorbent assay methods for avidity determination of antiphospholipid antibodies. J Clin Lab Anal 2017;31:e22121. DOI

Fialova L, Malbohan I, Malickova K. Avidity of anticardiolipin antibodies-A factor that could be important for their detection by ELISA methods. J Appl Biomed 2014;12:277-84. DOI

Almanzar G, Ottensmeier B, Liese J, Prelog M. Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate. J Immunol Methods 2013;387:36-42. DOI

Prince HE, Lape-Nixon M. Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy. Clin Vaccine Immunol 2014;21:1377-84. PubMed DOI

Ozarda Y. Reference intervals: current status, recent developments and future considerations. Biochem Med (Zagreb) 2016;26:5-16. PubMed DOI

Dimitrov JD, Lacroix-Desmazes S, Kaveri SV. Important parameters for evaluation of antibody avidity by immunosorbent assay. Anal Biochem 2011;418:149-51. PubMed DOI

Fialová L, Kuchař O, Petráčkova M, Malbohan I, Zima T. Avidity of anti-phospholipid antibodies in relation to their levels. Cent Eur J Immunol 2020;45:136-43. DOI

Sanmarco M, Gayet S, Alessi MC, Audrain M, de Maistre E, Gris JC, de Groot PG, Hachulla E, Harle JR, Sie P, Boffa MC. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007;97:949-54. PubMed DOI

Sanmarco M, Alessi MC, Harle JR, Sapin C, Aillaud MF, Gentile S, Juhan-Vague I, Weiller PJ. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses. Thromb Haemost 2001;85:800-5. PubMed DOI

Bertolaccini ML, Murru V, Sciascia S, Sanna G, Khamashta MA. The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE). Thromb Res 2012;130:914-8. DOI

Zhang S, Wu Z, Zhang W, Zhang F, Li Y, Liu Y. Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome. Clin Chim Acta 2019;495:205-9. DOI

Sanmarco M. ELISA for antiphosphatidylethanolamine antibody detection: high impact of assay buffer on results. J Immunol Methods 2010;358:9-16. DOI

Ke K, Strango ZI, Harper PE, Zhao M. Influence of Phosphatidylethanolamine Concentration and Composition on the Detection of Antiphosphatidylethanolamine Antibodies by ELISA. J Clin Lab Anal 2016;30:689-96. DOI

Vlachoyiannopoulos PG, Petrovas C, Tektonidou M, Krilis S, Moutsopoulos HM. Antibodies to beta 2-glycoprotein-I: urea resistance, binding specificity, and association with thrombosis. J Clin Immunol 1998;18:380-91. DOI

Cucnik S, Kveder T, Artenjak A, Ulcova Gallova Z, Swadzba J, Musial J, Iwaniec T, Stojanovich L, Alessandri C, Valesini G, Avcin T, Cohen Tervaert JW, Rozman B, Bozic B. Avidity of anti-beta2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Lupus 2012;21:764-5. PubMed DOI

Totland C, Aarseth J, Vedeler C. Hu and Yo antibodies have heterogeneous avidity. J Neuroimmunol 2007;185:162-7. DOI

Zeng Y, Lin Y, Wang X, Zhang Y, Peng F, Wang J, Jiang L, Liang S, Xiao Y. Assessment of a high-avidity IgG ANAs for the diagnosis and activity prediction of systemic lupus erythematosus. Clin Rheumatol 2020;39:2619-29. PubMed DOI

Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:127-32. PubMed DOI